Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma
International Journal of Molecular Sciences(2023)
摘要
The aim of this prospective clinical study was to evaluate the potential of the prostate specific membrane antigen (PSMA) targeting ligand, [Ga-68]-PSMA-Glu-NH-CO-NH-Lys-2-naphthyl-L-Ala-cyclohexane-DOTA ([Ga-68]Ga-PSMA-617) as a positron emission tomography (PET) imaging biomarker in recurrent glioblastoma patients. Patients underwent [Ga-68]Ga-PSMA-617 and O-(2-[F-18]-fluoroethyl)-L-tyrosine ([F-18]FET) PET scans on two separate days. [Ga-68]Ga-PSMA-617 tumour selectivity was assessed by comparing tumour volume delineation and by assessing the intra-patient correlation between tumour uptake on [Ga-68]Ga-PSMA-617 and [F-18]FET PET images. [Ga-68]Ga-PSMA-617 tumour specificity was evaluated by comparing its tumour-to-brain ratio (TBR) with [F-18]FET TBR and its tumour volume with the magnetic resonance imaging (MRI) contrast-enhancing (CE) tumour volume. Ten patients were recruited in this study. [Ga-68]Ga-PSMA-617-avid tumour volume was larger than the [F-18]FET tumour volume (p = 0.063). There was a positive intra-patient correlation (median Pearson r = 0.51; p < 0.0001) between [Ga-68]Ga-PSMA-617 and [F-18]FET in the tumour volume. [Ga-68]Ga-PSMA-617 had significantly higher TBR (p = 0.002) than [F-18]FET. The [Ga-68]Ga-PSMA-617-avid tumour volume was larger than the CE tumour volume (p = 0.0039). Overall, accumulation of [Ga-68]-Ga-PSMA-617 beyond [F-18]FET-avid tumour regions suggests the presence of neoangiogenesis in tumour regions that are not overly metabolically active yet. Higher tumour specificity suggests that [Ga-68]-Ga-PSMA-617 could be a better imaging biomarker for recurrent tumour delineation and secondary treatment planning than [F-18]FET and CE MRI.
更多查看译文
关键词
[Ga-68]Ga-PSMA-617,recurrent glioblastoma,positron emission tomography imaging of glioblastoma,theranostics for glioblastoma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要